Boster Bio cuts PicoBand antibody prices up to 50% for multi-target studies
Boster Bio is offering tiered discounts of up to 50% on eligible PicoBand antibodies for U.S. end-user customers, aiming to lower the cost of multi-target research. The promotion also comes with validation support and strict eligibility rules that keep the focus on scientifically justified experiments.
Why it matters: - Multi-target antibody panels can help researchers interpret pathways more accurately in inflammation, cancer signaling, apoptosis and drug response studies. - The discount may free up budget for controls, replicates, imaging or confirmatory work. - The offer is aimed at reducing cost without encouraging unnecessary antibody purchases.
What happened: - Boster Bio launched a tiered promotion on eligible PicoBand antibodies. - The offer gives 20% off two qualifying antibodies, 30% off three, 40% off four and 50% off five or more in the same order. - The discount is applied automatically in the cart for eligible U.S. end-user customers. - The promotion is available to researchers shopping through Boster Bio’s PicoBand Antibody Buy More, Save More program.
The details: - The tier is based on the number of eligible antibodies in the cart. - No promotional code is required. - Conjugated or labeled antibodies are excluded. - Products already in other promotions or discounted-price programs are excluded and do not count toward the qualifying quantity. - The discount applies only to the eligible product subtotal, not to shipping, taxes, handling fees or non-eligible items. - The offer is limited to end-user customers in the United States. - Distributors and resellers are not eligible. - Removing or canceling qualifying items can change the discount tier. - Final eligibility and pricing are confirmed at checkout. - Researchers are urged to verify each antibody’s target, species reactivity, validated applications, expected molecular weight or tissue localization and assay conditions before ordering. - Host species and secondary antibody compatibility remain important, especially in multiplexed imaging or staining workflows. - A PicoBand designation or promotional discount does not guarantee performance across every assay. - An antibody validated for Western blotting should not be assumed to work in immunohistochemistry, immunofluorescence, flow cytometry, immunoprecipitation or ELISA without supporting evidence. - Individual product pages include validation images, controls, protocols and application-specific details. - Controls should be built into the antibody plan from the start. - Western blot studies may require a stable loading control or total-protein normalization plus positive and negative samples. - Tissue staining and flow cytometry need different background and detection controls.
Between the lines: - The promotion rewards coordinated experimental design rather than bulk buying for its own sake. - Boster Bio is pairing the pricing offer with pre-purchase validation to reduce uncertainty around assay fit. - Validation evidence can help, but results from one sample or assay do not guarantee identical performance in every biological system. - The emphasis on controls underscores that cheaper reagents do not improve weak experimental design.
What's next: - Researchers can review eligible PicoBand antibody products and current pricing through the promotion page. - Participating antibodies can also be submitted for pre-purchase validation review. - Boster Bio says researchers should choose products based on scientific requirements first, then confirm application evidence and promotional eligibility. - Boster Biological Technology, founded in 1993 and headquartered in Pleasanton, California, continues to supply antibodies, ELISA kits, recombinant proteins, assay reagents and research services to life science labs. - The company says its documentation and validation resources support work in immunology, cancer biology, neuroscience and cell biology.
The bottom line: - Boster Bio is using a stepped discount and validation support to make multi-antibody research cheaper while pushing buyers to keep controls and assay-specific evidence front and center.
More information: the company's social channels
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The California STEM Reporter
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.